fashion -WSS

fashion

author：hotspot 2025-09-30 22:28:31 - browse：9

A dosage of Wegovy, a drug used for weight loss — Amanda Andrade-Rhoades/AP

U.S. regulators approved a label expansion for Novo Nordisk’s obesity drug Wegovy to tout its benefits for the heart, a move that could boost demand and insurance coverage for the already highly popular treatment.

The new label indicates that Wegovy can be used to reduce the risk of major heart complications — including heart attack, stroke, or cardiovascular-related deaths — for people with overweight or obesity and existing heart disease, Novo said in a statement Friday.

The decision was based on results of a large, five-year trial that showed Wegovy cut the risk of cardiovascular problems by 20% in that population. This is the first time a weight loss treatment has been approved to also help improve heart outcomes, the FDA said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： BD to buy Edwards patient monitoring unit for $4.2 billion

WSS

Illumina board agrees to spin off Grail, as divestment plans proceed

Alabama frozen embryo ruling has major implications for IVF clinics

NIH study of ME/CFS points to clear biological hallmarks

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

Medicare Advantage's lean provider networks lead CMS complaints

Stopping antidepressants leads to symptoms for 1 in 6 patients

hotspot

fashion

knowledge

New air purifier tech could be key to improving indoor air quality

Illumina board agrees to spin off Grail, as divestment plans proceed

Medical leaders decry Supreme Court decision on affirmative action

A new initiative will help leaders fight the next pandemic

What does generative AI mean for health care? We asked experts

The Harvard botanist who searched for psychedelics in the Amazon

Supreme Court strikes down use of affirmative action

FDA approves Moderna’s RSV vaccine, its second licensed product

Cancer drug shortages should be causing more outrage

New documents shed light on MD Anderson Cancer Institute feud

focus

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

A new initiative will help leaders fight the next pandemic

With competition flaring, obesity drug hits goal in liver disease study

ASCO Daily Recap: CAR

Alabama frozen embryo ruling has major implications for IVF clinics

CMS got Medicare Advantage quality rating wrong, judge rules

focus

focus

Wikipedia

focus